Lazard Asset Management’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.7M Sell
33,119
-629
-2% -$207K 0.02% 429
2025
Q4
$11.8M Sell
33,748
-2,473
-7% -$836K 0.02% 390
2025
Q3
$11.7M Sell
36,221
-19,664
-35% -$6.12M 0.02% 396
2025
Q2
$21.7M Buy
55,885
+2,983
+6% +$1.2M 0.03% 382
2025
Q1
$23M Buy
52,902
+13,063
+33% +$5.24M 0.04% 320
2024
Q4
$14.7M Sell
39,839
-7,120
-15% -$2.98M 0.02% 396
2024
Q3
$24.4M Sell
46,959
-86,127
-65% -$46M 0.03% 308
2024
Q2
$72.1M Sell
133,086
-9,671
-7% -$5.11M 0.09% 167
2024
Q1
$74M Buy
142,757
+15,586
+12% +$7.75M 0.09% 171
2023
Q4
$60M Buy
127,171
+1,050
+0.8% +$486K 0.08% 189
2023
Q3
$54.9M Buy
126,121
+27,659
+28% +$12.5M 0.07% 189
2023
Q2
$43.7M Sell
98,462
-987
-1% -$455K 0.05% 229
2023
Q1
$45.7M Sell
99,449
-3,933
-4% -$1.87M 0.06% 242
2022
Q4
$53M Sell
103,382
-64,983
-39% -$33M 0.07% 221
2022
Q3
$76.5M Sell
168,365
-10,446
-6% -$5M 0.11% 167
2022
Q2
$86.3M Sell
178,811
-6,539
-4% -$3.23M 0.12% 154
2022
Q1
$91M Sell
185,350
-2,052
-1% -$938K 0.11% 175
2021
Q4
$86.9M Sell
187,402
-28,808
-13% -$12.1M 0.09% 195
2021
Q3
$80.6M Sell
216,210
-10,171
-4% -$3.87M 0.09% 206
2021
Q2
$86.4M Buy
226,381
+16,599
+8% +$6.34M 0.1% 192
2021
Q1
$75.3M Buy
209,782
+51,694
+33% +$16.6M 0.09% 187
2020
Q4
$50.8M Sell
158,088
-58,111
-27% -$17.8M 0.06% 242
2020
Q3
$58.1M Buy
216,199
+57,759
+36% +$15.5M 0.08% 194
2020
Q2
$41.7M Sell
158,440
-514,184
-76% -$137M 0.06% 213
2020
Q1
$153M Sell
672,624
-166,711
-20% -$45.4M 0.28% 78
2019
Q4
$254M Buy
839,335
+202,126
+32% +$55.6M 0.36% 73
2019
Q3
$153M Sell
637,209
-161,456
-20% -$44.2M 0.25% 93
2019
Q2
$225M Buy
798,665
+676,257
+552% +$185M 0.37% 70
2019
Q1
$35.1M Sell
122,408
-62,331
-34% -$18M 0.06% 222
2018
Q4
$48.5M Sell
184,739
-15,415
-8% -$4.24M 0.09% 159
2018
Q3
$54.9M Buy
200,154
+33,997
+20% +$8.83M 0.09% 162
2018
Q2
$39.5M Buy
166,157
+3,609
+2% +$836K 0.07% 196
2018
Q1
$35.7M Buy
162,548
+1,373
+0.9% +$323K 0.06% 203
2017
Q4
$36.3M Buy
161,175
+55,706
+53% +$11.9M 0.06% 209
2017
Q3
$20M Buy
105,469
+59,559
+130% +$11.3M 0.04% 286
2017
Q2
$8.64M Sell
45,910
-530
-1% -$95.2K 0.02% 457
2017
Q1
$7.68M Sell
46,440
-815
-2% -$130K 0.01% 502
2016
Q4
$6.79M Sell
47,255
-1,450
-3% -$194K 0.01% 494
2016
Q3
$6.1M Sell
48,705
-2,150
-4% -$278K 0.01% 490
2016
Q2
$6.68M Buy
50,855
+50
+0.1% +$6.84K 0.01% 466
2016
Q1
$7.06M Buy
50,805
+7,170
+16% +$958K 0.02% 446
2015
Q4
$6.08M Buy
43,635
+11,365
+35% +$1.57M 0.01% 488
2015
Q3
$4.52M Buy
32,270
+32,241
+111,176% +$4.85M 0.01% 498
2015
Q2
$4K Buy
+29
New +$4.63K ﹤0.01% 1092
2013
Q3
Sell
-36,740
Closed -$3.01M 974
2013
Q2
$3.01M Buy
+36,740
New +$2.75M 0.01% 577

Other funds holding ELV

Lazard Asset Management's ELV Position: Q1 2026 in Review

Lazard Asset Management reduced its Elevance Health (ELV) stake by 1.9% in Q1 2026, selling an estimated $207K and leaving 33,119 shares worth $9.7M. The position accounts for 0.02% of the portfolio, ranked #429.

Lazard Asset Management first reported a position in ELV in Q2 2013 and has held it in 45 quarters since. The position peaked at $254M in Q4 2019. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Lazard Asset Management held 33,119 shares of Elevance Health worth $9.7M as of Q1 2026.
  • Lazard Asset Management sold 629 Elevance Health shares in Q1 2026, an estimated $207K.
  • Elevance Health made up 0.02% of Lazard Asset Management's portfolio in Q1 2026, its #429 holding.
  • Lazard Asset Management first reported a position in Elevance Health in Q2 2013 and has held it in 45 quarters since.
  • Lazard Asset Management's Elevance Health position peaked at $254M in Q4 2019.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.